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ORIGINAL RESEARCH

National Trends in Admission and In-Hospital Mortality of Patients
With Heart Failure in the United States (2001–2014)
Emmanuel Akintoye, MD, MPH; Alexandros Briasoulis, MD, PhD; Alexander Egbe, MD, MPH; Shannon M. Dunlay, MD, MS;
Sudhir Kushwaha, MD; Diane Levine, MD; Luis Afonso, MD; Dariush Mozaffarian, MD, DrPH; Jarrett Weinberger, MD

Background-—To investigate heart failure (HF) hospitalization trends in the United States and change in trends after publication of
management guidelines.

Downloaded from http://jaha.ahajournals.org/ by guest on December 2, 2017

Methods and Results-—Using data from the National Inpatient Sample and the US Census Bureau, annual national estimates in HF
admissions and in-hospital mortality were estimated for years 2001 to 2014, during which an estimated 57.4 million HF-associated
admissions occurred. Rates (95% conﬁdence intervals) of admissions and in-hospital mortality among primary HF hospitalizations
declined by an average annual rate of 3% (2.5%–3.5%) and 3.5% (2.9%–4.0%), respectively. Compared with 2001 to 2005, the
average annual rate of decline in primary HF admissions was more in 2006 to 2009 (ie, 3.4% versus 1.1%; P=0.02). In 2010 to
2014, primary HF admission continued to decline by an average annual rate of 4.3% (95% conﬁdence interval, 3.9%–5.1%), but this
was not signiﬁcantly different from 2006 to 2009 (P=0.14). In contrast, there was no further decline in in-hospital mortality trend
after the guideline-release years. For hospitalizations with HF as the secondary diagnosis, there was an upward trend in admissions
in 2001 to 2005. However, the trend began to decline in 2006 to 2009, with an average annual rate of 2.4% (95% conﬁdence
interval, 0.8%–4%). Meanwhile, there was a consistent decline in in-hospital mortality by an average annual rate of 3.7% (95%
conﬁdence interval, 3.3%–4.2%) during the study period, but the decline was more in 2006 to 2009 compared with 2001 to 2005
(ie, 5.4% versus 3.4%; P<0.001). Beyond 2009, admission and in-hospital mortality rates continued to decline, although this was
not signiﬁcantly better than the preceding interval.
Conclusions-—From 2001 to 2014, HF admission and in-hospital mortality rates declined signiﬁcantly in the United States; the
greatest improvements coincided with the publication of the 2005 American College of Cardiology/American Heart Association HF
guidelines. ( J Am Heart Assoc. 2017;6:e006955. DOI: 10.1161/JAHA.117.006955.)
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H

eart failure (HF) constitutes a major public health
burden with an estimated prevalence of >5.7 million in
the United States and >23 million worldwide.1,2 There was a
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striking increase in its prevalence from the 1970s through the
1990s, during which time it reached an epidemic level.3,4
Although recent reports suggest that the incidence of HF has
plateaued in the general population and is decreasing in some
groups,1,5,6 an estimated 915 000 individuals are still diagnosed as having HF in the United States each year.
Furthermore, because of the aging of the population and
improved survival after diagnosis, the prevalence of HF is still
increasing and is estimated to increase by 46% from 2012 to
2030, which will result in >8 million adults with a diagnosis of
HF.2,7
To further understand the epidemiological characteristics
and burden of HF, an assessment of the trends in its
admission and mortality rates is imperative. More so, an
insight into these trends serves as a quality metric for
evaluating the advances made in healthcare delivery and
national guidelines aimed at improving patient outcomes.
Prior studies on trends in HF hospitalization and in-hospital
mortality in the United States demonstrated a decline
between 1998 and 2009.8–10 However, there is a lack of
Journal of the American Heart Association
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the involved individuals did not receive a test material (ie, drug
or device) as participants in the study.

What Is New?
• From 2001 to 2014, there has been a signiﬁcant decline in
heart failure–related admissions and in-hospital mortality in
the United States.
• During the study period, we found that the greatest decline
in these hospitalization outcomes coincided with the
publication of the 2005 American College of Cardiology/
American Heart Association heart failure management
guidelines.

What Are the Clinical Implications?
• These ﬁndings highlight the importance of concerted efforts
(including guideline-directed care) aimed at improving
outcomes in patients with heart failure.
Downloaded from http://jaha.ahajournals.org/ by guest on December 2, 2017

evidence on recent trends in HF hospitalization outcomes
after 2009 and detailed assessment of progress made after
publication of national guidelines.
To address these gaps in knowledge, we therefore
performed an in-depth analysis of the national trends in
admission and in-hospital mortality in patients with HF with
the goal of providing an assessment of the progress made
during the past decade through concerted efforts, such as the
periodic publication of national HF management guidelines by
the American College of Cardiology (ACC)/American Heart
Association (AHA) joint task force.

Patient Population
We included all adult patients (aged ≥18 years) with a primary
or secondary diagnosis of HF in the NIS database between
2001 and 2014. A primary HF diagnosis refers to hospitalizations mainly attributable to HF, whereas a secondary
diagnosis refers to hospitalizations in patients with chronic HF
who were admitted for reasons other than HF. These were
identiﬁed via the following International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM)
diagnosis codes, as recommended by the ACC/AHA task
force on performance measures: 402.01, 402.11, 402.91,
404.01, 404.03, 404.11, 404.13, 404.91, 404.93, and 428.12
HF was classiﬁed as a primary diagnosis if any of the codes
appear as the ﬁrst diagnosis in the NIS database. Otherwise, it
was classiﬁed as secondary if it occurs at any other level of
diagnoses.

Covariates
Data on patient- and hospital-level characteristics were
provided for each hospitalization in the NIS database.
However, identiﬁable variables were not included to preserve
both patient and hospital privacies. Patient-level factors,
including demographics, diagnoses, comorbidities, in-hospital
procedures, and disposition, as well as hospital-level factors,
including bed size, location, and total number of hospitalizations, are available via the NIS database.

Methods
Data Source

End Points

This study was conducted using the National Inpatient
Sample (NIS) of the Health Care Utilization Project sponsored by the Agency for Healthcare Research and Quality.
Details of the design and description of the NIS are available
online.11 Brieﬂy, this nationally representative database,
which represents the largest all-payer inpatient care
database in the United States, contains yearly encounterlevel information of hospital stays compiled in a uniform
format, with privacy protection of individual patients. NIS
approximates a 20% stratiﬁed sample of discharges from
nonfederal, short-term, general, and other specialty hospitals
in the United States. To derive national estimates from the
sample, the Agency for Healthcare Research and Quality
provides a trend/discharge weight that accounted for the
sampling design.
The study was considered exempt from formal review by
the Wayne State University (Detroit, MI) institutional review
board because it involves a deidentiﬁed public database and

The main end points in this study were trends in admission
and in-hospital mortality in patients admitted with a primary
diagnosis of HF. In addition, we evaluated similar trends in
patients admitted with a secondary diagnosis of HF. Inhospital mortality was available in the NIS data as a
categorical variable (yes/no).

DOI: 10.1161/JAHA.117.006955

Statistical Analysis
National estimates, including measure of central tendencies,
rates, and proportions, were calculated using the hospitallevel trend weights provided for the NIS by the Agency for
Healthcare Research and Quality. To quantify comorbidities
per hospitalization, we used the Deyo modiﬁcation of the
Charlson comorbidity index (ie, Charlson/Deyo score) to
identify and classify coexisting conditions (Table S1).13
Baseline characteristics were compared using the v2 test
for categorical variables and the ANOVA or Kruskal-Wallis
Journal of the American Heart Association
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Table 1. Characteristics of Hospital Admissions With Primary or Secondary Diagnosis of HF, According to Survival Status at
Discharge*
Characteristics

Total

Survived Until Hospital
Discharge

In-Hospital Mortality

Unweighted no. (%)

12 007 813 (100)

11 305 810 (94.2)

702 003 (5.8)

Weighted no. (%)

57 350 384 (100)

54 030 898 (94.2)

3319 485 (5.8)

Age, mean (SD), y

P Value

73.3 (13.7)

73.0 (13.8)

77.6 (12.2)

<0.001

<65 y, %

24.7

25.3

14.4

<0.001

≥65 y, %

75.3

74.7

85.6

Female sex, %

53.5

53.5

52.0

White

72.9

72.7

77.3

Black

15.7

16.0

11.3

Hispanic

7.0

7.0

6.5

Asian

1.7

1.7

2.2

2.7

2.7

2.7

2.0 (3.0)

2.0 (3.0)

3.0 (2.0)

0

8.2

8.5

4.4

1

23.1

23.4

19.2

≥2

68.6

68.2

76.4

First quartile

32.0

32.1

29.7

Second quartile

26.8

26.8

26.4

Third quartile

22.8

22.8

23.2

18.4

18.3

20.7

Medicare

77.6

77.4

81.7

Medicaid

6.7

6.9

4.4

Private

11.8

11.9

10.4

Self-pay

2.1

2.1

1.5

Small

14.4

14.4

14.0

Medium

25.3

25.3

25.2

Large

60.3

60.3

60.8

Northeast

19.3

19.1

21.8

Midwest

24.6

24.8

21.5

South

40.2

40.2

39.3

West

15.9

15.8

17.4

Rural

15.4

15.5

14.7

Urban nonteaching

42.4

42.3

44.0

Urban teaching

42.2

42.2

41.3

<0.001

Race, %
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Others
Charlson/Deyo score, median (IQR)

†

<0.001

<0.001

Charlson/Deyo score, %
<0.001

Median household income by zip code, %

Fourth quartile

<0.001

‡

Expected primary payer, %

<0.001

Hospital bed size, %
<0.001

Hospital region, %
<0.001

Hospital location/teaching status, %
<0.001

Continued
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Table 1. Continued
Characteristics

Total

Survived Until Hospital
Discharge

In-Hospital Mortality

P Value

Length of stay, median (IQR), d

5.0 (5.0)

5.0 (5.0)

6.0 (10)

<0.001

0–2 d, %

22.4

22.1

27.8

3–4 d, %

26.8

27.5

15.9

≥5 d, %

50.8

50.5

56.3

<0.001

HF indicates heart failure; and IQR, interquartile range.
*Secondary diagnosis of HF refers to patients with chronic HF who were admitted for reasons other than HF.
†
Refers to the Deyo modiﬁcation of the Charlson comorbidity score/index.
‡
Medicare and Medicaid beneﬁciaries include both fee-for-service and managed care, whereas private insurance includes Blue Cross, commercial carriers, and private health maintenance
organizations and preferred provider organizations.
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test (as appropriate) for continuous variables. Standardized
national rates of hospital admission were calculated for each
year (per 100 000 people) by dividing the estimated number
of admissions by the US population of adults ≥18 years of
age for that year. National population estimates were
obtained for each year from the US census bureau,14 and
annual rates were age and sex standardized to the 2014
population using the direct standardization method to
enhance unbiased comparison across the years. Yearly inhospital mortality was calculated as percentage of HF
admissions for that year. Thereafter, the average annual
percentage change in admission and mortality was calculated using Poisson regression modeling with robust variance, in which calendar year was modeled as a continuous
independent variable.
To evaluate trends after the 2005 and 2009 ACC/AHA
guideline updates for the management of HF in adults,15,16 we
additionally evaluated trends in 3 intervals demarcated by the
guideline-release years (ie, 2001–2005, 2006–2009, and
2010–2014). Change in trend from one interval to the next
(ie, between 2 adjoining intervals) was evaluated via piecewise regression modeling with robust variance.
Last, stratiﬁed analysis by categories of age (<65 and
≥65 years), sex, and race was conducted for in-hospital
mortality among patients with HF as a primary diagnosis.
Analyses were performed using STATA 14 (StataCorp,
College Station, TX) and SPSS version 20.0 (IBM Corp,
Armonk, NY), with a 2-tailed level of signiﬁcance set at 0.05.

Results
The estimated number of hospital admissions in the United
States with HF as the primary or secondary diagnosis was
>57 million between 2001 and 2014. In total, 75.3% of these
admissions occurred in patients ≥65 years and 53.5% were
women (Table 1). Racial distribution was 72.9% white, 15.7%
black, 7% Hispanic, 1.7% Asian, and 2.7% others.
DOI: 10.1161/JAHA.117.006955

Approximately on third of the admissions occurred among
patients within the ﬁrst quartile of household income, and
most (77.6%) were enrolled in the Medicare insurance
program. Geographically, there were more admissions in the
south (40.2%) compared with other regions of the country.

Trends in HF as a Primary Diagnosis
Hospitalizations
An estimated 14.6 million hospitalizations with HF as the
primary diagnosis (ie, 25.5% of total HF-associated admissions) occurred in the United States between 2001 and 2014.
Most of the hospitalizations occurred between the ages of 75
and <85 years (29.5%), among women (51.5%), and in whites
(68.3%; Table S2). The rates of these primary HF admissions
declined from 563 per 100 000 people in 2001 to 398 per
100 000 people in 2014 (Figure 1A), with an average annual
decline of 3% (95% conﬁdence interval [CI], 2.5%–3.5%;
P<0.001; Table 2).
When we evaluated rates of decline within the 3 intervals
of the ACC/AHA HF guidelines, there was a decreasing trend
within each interval, but the magnitude of the decline was
higher in the later intervals (ie, average annual rate of decline
was 1.1% [95% CI, 0.18%–1.9%; P=0.02] for the ﬁrst interval,
3.4% [95% CI, 2.4%–4.4%; P<0.001] for the second interval,
and 4.3% [95% CI, 3.9%–5.9%; P<0.001] for the third interval)
(Figure 1A). We found a signiﬁcant change in trend after the
2005 guidelines compared with before the guidelines.
Speciﬁcally, we found that the magnitude of the average
annual rate of decline in primary HF admission was 2.4% (95%
CI, 0.39%–4.4%; P=0.02) more in the 2006 to 2009 interval
compared with the preceding 2001 to 2005 interval. However,
compared with the 2006 to 2009 interval, the change in trend
in 2010 to 2014 did not reach statistical signiﬁcance. The
decline (ﬁrst versus third interval) was more pronounced in
ages between 75 and <85 years (31.9% versus 27%), as well
as among women (53.6% versus 49.6%), whites (70.3% versus
Journal of the American Heart Association
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Figure 1. A, Trends in primary heart failure admission rates within intervals demarcated by the 2005 and
2009 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines. There was a
signiﬁcant change in trend in the 2005 to 2009 interval (red) compared with before 2005 (blue). There was
a nonsigniﬁcant change in trend after 2009 (orange) compared with the prior interval. B, Trends in inhospital mortality in patients with a primary diagnosis of heart failure within intervals demarcated by the
2005 and 2009 ACC/AHA guidelines. There was no signiﬁcant change in trend in the 2005 to 2009 interval
(red) compared with before 2005 (blue). However, the trend appeared to have plateaued after the 2009
guidelines (orange). CI indicates conﬁdence interval.

67%), Hispanics (8.2% versus 7.6%), Medicare beneﬁciaries
(76.1% versus 74.9%), and privately insured patients (12.6
versus 11.6; Table 3). However, the degree of comorbid
conditions per HF hospitalization, as measured by the
Charlson/Deyo comorbidity score, increased over the years
(eg, hospitalizations with a score ≥2 increased from 43.5% in
the ﬁrst interval to 63.6% in the third interval). In addition,
DOI: 10.1161/JAHA.117.006955

there was an increase in hospitalization in urban teaching
hospitals (35.1% versus 46.7%) with an associated decrease in
rural (17.9% versus 14.2%) and urban (47% versus 39.1%)
nonteaching hospitals. Last, there was a decrease in the
median (interquartile range) length of stay over the 3 intervals
from 5.0 (4.0) days in the ﬁrst interval to 4.0 (4.0) days in the
third interval.
Journal of the American Heart Association
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<0.001
!5.4 (!6.2 to !4.7)
<0.001
!3.4 (!4.0 to !2.7)
Secondary HF mortality

<0.001
2.6 (2.4 to 2.8)
Secondary HF admission

!4.2 (!4.5 to !3.9)
Primary HF mortality

CI indicates conﬁdence interval; and HF, heart failure.
*To assess average annual percentage change within each interval, the guideline-release years were considered as the last year of the preceding interval and the ﬁrst year of the following interval. Negative estimates indicate declining trends,
whereas positive estimates indicate increasing trends.
†
Although there was no overall linear trend from 2001 through 2014, there was a linear trend in piecewise analysis within the 2001 to 2005 and 2005 to 2009 intervals.

!3.7 (!4.2 to !3.3)
0.02
!1.3 (!2.4 to !0.27)

0.09

!1.2 (!1.6 to 0.19)
0.004

!2.4 (!4.0 to !0.80)

<0.001

!3.9 (!5.6 to !2.3)
<0.001

<0.001

0.40†

!0.22 (!0.72 to 0.29)

<0.001

!1.0 (!1.8 to !0.23)

0.01

!3.5 (!4.0 to !2.9)

<0.001

!3.0 (!3.5 to !2.5)
<0.001

!4.3 (!5.1 to !3.9)
<0.001

!3.4 (!4.4 to !2.4)
!1.1 (!1.9 to !0.18)
Primary HF admission

0.02

2001–2014
P Value
for Trend
2010–2014
P Value
for Trend
2006–2009
P Value
for Trend
2001–2005
Variable

Table 2. Average Annual Percentage Change in Rates (With 95% CIs) of HF Admissions and In-Hospital Mortality*
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Mortality
In-hospital mortality among patients hospitalized with a
primary diagnosis of HF declined from 4.5% in 2001 to 2.9%
in 2014, although the rate of decline gradually diminished in
the past few years of the study period (Figure 1B). Overall, the
average annual rate of decline in mortality in patients with a
primary diagnosis of HF was 3.5% (95% CI, 2.9%–4.0%;
P<0.001; Table 2). Compared with those who survived to
hospital discharge, those who died were older (70.4% versus
51.2% were aged ≥75 years), were more likely to be white
(78.4% versus 67.9%), had a higher Charlson/Deyo comorbidity score (59.4% versus 53.8% had a score of ≥2), were
enrolled in the Medicare insurance program (81.5% versus
75%), and were in rural (17.5% versus 16.1%) and urban
(44.3% versus 43.5%) nonteaching hospitals (Table S2). In
addition, mortality was highest within the ﬁrst 2 days of
admission, decreased to a nadir on days 3 and 4, and trended
up afterwards (Figure 2).
When we evaluated changes in the in-hospital mortality
rate in the 3 time intervals of the ACC/AHA HF guidelines, the
observed in-hospital mortality rate decreased in each interval,
but the magnitude of the decline diminished in the later
intervals: the average annual rate of decline was 4.2% (95%
CI,3.9%–4.5%; P<0.001) in the 2001 to 2005 interval, 3.9%
(95% CI, 2.3%–5.6%; P<0.001) in the 2006 to 2009 interval,
and 1.0% (95% CI, 0.23%–1.8%; P=0.01) in the 2010 to 2014
interval (Table 2). There was no statistically signiﬁcant
difference in the rate of decline in the 2006 to 2009 interval
(ie, after publication of the 2005 guidelines) compared with
the 2001 to 2005 interval, whereas the trend approached a
plateau after the 2009 guidelines (Figure 1B).
In stratiﬁed analysis (Table 4), in-hospital mortality was
higher among patients aged ≥65 years compared with
<65 years, although there was a slight closing of the gap in
the later years compared with the earlier part of the study
period (Figure 3A). Closing of the gap was mainly attributable
to a faster rate of decline in in-hospital mortality among
patients aged ≥65 years, with an average annual decline of
3.2% (95% CI, 2.8%–3.7%; P<0.001) compared with 2.3% (95%
CI, 1.4%–4.2%; P<0.001) among patients aged <65 years. In
addition, the decline in in-hospital mortality plateaued among
patients aged <65 years, whereas it was still decreasing
among patients aged ≥65 years in the last interval of the
study period (ie, 2010–2014). When we stratiﬁed analysis by
sex, we found that in-hospital mortality was higher in men at
the beginning of the study (ie, year 2001) (Figure 3B).
However, the rate of decline was faster in men (5.5% [95%
CI, 5.0%–6.3%]; P<0.001) than in women (3.2% [95% CI, 2.5%–
3.9%]; P<0.001) during the ﬁrst interval, and the apparent sex
gap seems to have closed by the third interval. Last, stratiﬁed
analysis by race showed that in-hospital mortality was highest
Journal of the American Heart Association
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Table 3. Trends in Patient- and Hospital-Level Characteristics Among Hospitalizations With a Primary Diagnosis of HF
Characteristics

2001–2005

2006–2009

2010–2014

Hospitalization (per 100 000 people)

553

489

416

Age, mean (SD), y

72.7 (13.9)

72.5 (14.5)

72.5 (14.4)

18–<45 y, %

4.0

4.3

4.2

45–<55 y, %

7.8

8.8

8.5

55–<65 y, %

13.7

14.4

15.2

65–<75 y, %

22.1

20.6

20.9

75–<85 y, %

31.9

29.3

27.0

≥85 y, %

20.5

22.6

24.2

Female sex, %

53.6

50.8

49.6

White

70.3

67.6

67.0

Black

17.8

19.6

20.8

Hispanic

8.2

8.1

7.6

Asian

1.6

1.8

1.9

Others

2.0

3.0

2.8

1.0 (1.0)

2.0 (2.0)

2.0 (2.0)

0

24.1

18.9

15.8

1

32.4

24.9

20.7

≥2

43.5

56.2

63.6

First quartile

33.3

33.5

33.4

Second quartile

26.9

26.9

26.3

Third quartile

22.3

21.8

22.7

Fourth quartile

17.5

17.8

17.6

Medicare

76.1

74.3

74.9

Medicaid

7.0

7.5

8.3

Private

12.6

12.8

11.6

Self-pay

2.6

3.3

3.2

Small

13.5

15.2

16.1

Medium

26.1

24.9

26.0

Large

60.4

59.9

57.9

Northeast

20.1

19.1

20.4

Midwest

23.0

23.3

23.2

South

42.4

42.0

40.7

West

14.5

15.6

15.7

P Value

0.002

<0.001

<0.001

Race, %

Downloaded from http://jaha.ahajournals.org/ by guest on December 2, 2017

Charlson/Deyo score, median (IQR)

<0.001

<0.001

Charlson/Deyo score, %
<0.001

Median household income by
zip code, %
<0.001

Expected primary payer†, %
<0.001

Hospital bed size, %
0.02

Hospital region, %
<0.001

Continued
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Table 3. Continued
Characteristics

2001–2005

2006–2009

2010–2014

17.9

16.1

14.2

Urban nonteaching

47

44.1

39.1

Urban teaching

35.1

39.8

46.7

5.0 (4.0)

4.0 (4.0)

4.0 (4.0)

0–2 d, %

24.8

26.5

26.2

3–4 d, %

30.9

31.4

32.3

≥5 d, %

44.3

42.2

41.5

P Value

Hospital location/teaching status, %
Rural

Length of stay, median (IQR), d

<0.001
<0.001
<0.001

HF indicates heart failure; and IQR, interquartile range.
*Refers to the Deyo modiﬁcation of the Charlson comorbidity score/index. see reference 13 (under reference section):
†
Medicare and Medicaid beneﬁciaries include both fee-for-service and managed care, whereas private insurance includes Blue Cross, commercial carriers, and private health maintenance
organizations and preferred provider organizations.
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among whites compared with other races (Figure 3C). There
was a declining trend across all 4 races, but the average
annual rate of decline was highest among blacks (4.4% [95%
CI, 3.7%–5.1%]; P<0.001) and lowest among whites (3.4%
[95% CI, 3.0–3.7%).

Trends in HF as a Secondary Diagnosis
Hospitalizations
An estimated 42.7 million hospital admissions occurred with
HF as a secondary diagnosis between 2001 and 2014. Similar
to primary HF admissions, most of the secondary HF
admissions occurred between the ages of 75 and <85 years
(30.8%), among women (54.1%), and among whites (74.5%;
Table S3). However, unlike primary HF admissions, the annual
rate of secondary HF admissions initially increased from 1366

per 100 000 people in 2001 to a peak of 1502 per 100 000
people in 2006 and thereafter declined for the next 3 years to
a somewhat plateau afterwards (although there was a
temporary spike in 2011; Figure 4A).
When we evaluated the secondary HF admission rates in
the 3 time intervals of the ACC/AHA guidelines, there was a
signiﬁcant change in trend after the publication of the
guidelines in 2005 but no signiﬁcant change after 2009
(Figure 4A, Table 2). Speciﬁcally, secondary HF hospitalization rates increased in the ﬁrst interval (ie, 2001–2005), and
then decreased in the second interval (ie, 2006–2009;
magnitude of change, 4.8% [95% CI, 3.1%–6.4%; P<0.001]);
the admission rates plateaued after the 2009 guidelines (ie,
third interval). Across the 3 intervals (from ﬁrst to third), the
age at admission decreased (eg, percentage of admissions
with age ≥65 years decreased from 78.7% to 73.8%; Table 5).
Also, there was a decreasing percentage of women (55.9% to
52.4%), whites (77% to 72.7%), Medicare beneﬁciaries (79.7%
to 77.8%), and rural (17.2% to 13.2%) and urban (45.5% to
37.7%) nonteaching hospital admissions. However, the degree
of comorbid conditions per hospitalization, as measured by
the Charlson/Deyo comorbidity score, increased over the
years (eg, hospitalizations with a score of ≥2 increased from
68.1% in the ﬁrst interval to 78.3% in the third interval). Last,
there was a decrease in the median (interquartile range)
length of stay over the 3 intervals from 6.0 (6.0) days in the
ﬁrst interval to 5.0 (5.0) days in the third interval.

Mortality

Figure 2. Percentage in-hospital mortality by total length of
hospital stay among heart failure (HF)–related admissions in the
United States. Primary HF indicates HF as a primary diagnosis;
and secondary HF, HF as a secondary diagnosis.

DOI: 10.1161/JAHA.117.006955

In-hospital mortality in patients with a secondary diagnosis of
HF declined from 8.3% in 2001 to 5.6% in 2014 (Figure 4B).
The average annual rate of decline was 3.7% (95% CI, 3.3%–
4.2%; P<0.001; Table 2). Compared with those who survived
to hospital discharge, those who died were older (66.4%
versus 53% were aged ≥75 years) and were less likely to be
Journal of the American Heart Association
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Table 4. Age-, Sex-, and Race-Speciﬁc Average Annual Percentage Change in Mortality in Patients Admitted for HF*
Variable

2001–2005

P Value
for Trend

2006–2009

P Value
for Trend

2010–2014

P Value
for Trend

0.06

0.01 (!2.2 to 2.3)

0.99

2001–2014

P Value
for Trend

Age categories, y
<65
≥65
Sex
Male
Female
Race
White
Black
Hispanic
Asian

!2.9 (!4.5 to !1.2)

0.001

!2.3 (!4.6 to 0.11)

!2.3 (!4.2 to !1.4)

<0.001

!3.8 (!3.9 to !3.7)

<0.001

!3.9 (!5.2 to !2.7)

<0.001

!0.63 (!1.0 to !0.22)

0.003

!3.2 (!3.7 to !2.8)

<0.001

!5.5 (!6.3 to !5.0)

<0.001

!3.6 (!6.0 to !1.1)

0.004

0.75 (!0.10 to 1.6)

0.09

!3.7 (!4.6 to !2.8)

<0.001

!3.2 (!3.9 to !2.5)

<0.001

!4.2 (!4.9 to !3.4)

<0.001

!1.4 (!2.0 to !0.84)

<0.001

!3.3 (!3.6 to !2.9)

<0.001

!4.2 (!4.3 to !4.0)

<0.001

!4.0 (!5.6 to !2.3)

<0.001

!1.7 (!2.3 to !1.1)

<0.001

!3.4 (!3.7 to !3.0)

<0.001

!4.3 (!5.3 to !3.3)

!2.9 (!5.3 to !0.37)
!9.2 (!15 to !2.9)

<0.001
0.03
0.004

!5.0 (!6.2 to !3.8)

!4.6 (!7.4 to !1.7)

!4.5 (!8.7 to !0.15)

<0.001

!1.1 (!2.0 to !0.26)

0.01

0.002

2.2 (!0.78 to 5.2)

0.15

0.04

0.51 (!6.7 to 8.2)

0.89

!4.4 (!5.1 to !3.7)

!3.8 (!5.1 to !2.6)

!3.7 (!5.4 to !2.0)

<0.001
<0.001
<0.001
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HF indicates heart failure.
*Negative estimates indicate declining trends, whereas positive estimates indicate increasing trends.

women (52.1% versus 54.3%) but were more likely to be white
(77.1% versus 74.3%), to be a Medicare beneﬁciary (81.8%
versus 78.2%), to have a higher Charlson/Deyo comorbidity
score (79.5% versus 73.2% had a score ≥2), and to be in an
urban nonteaching hospital (44% versus 41.9%).
In addition, similar to HF as a primary diagnosis, mortality
was highest within the ﬁrst 2 days of admission, decreased to
a nadir on days 3 and 4, and trended up afterwards (Figure 2).
Overall, patients with HF were more likely to die while
hospitalized for another reason (ie, HF as a secondary
diagnosis) than while hospitalized for HF.
When we evaluated the change in the in-hospital mortality
in each of the 3 time intervals of the ACC/AHA HF guidelines,
the rate decreased in each interval, but the magnitude of the
decline was greatest in the second interval. The average
annual rate of decline was 3.4% (95% CI, 2.7%–4.0%; P<0.001)
for the ﬁrst interval, 5.4% (95% CI, 4.7%–6.2%; P<0.001) for
the second interval, and 1.3% (95% CI, 0.27%–2.4%; P=0.02)
for the third interval (Table 2). There was a signiﬁcant change
in trends after both guidelines were published, but only after
2005 was the trend a decline (Figure 4B).

Discussion
In this nationally representative sample of hospital admissions
in the United States, we found that, despite an increase in
comorbidity burden, the rate of hospital admission primarily
for HF declined from 2001 through 2014 while the trend in HF
as a secondary diagnosis initially increased to a peak in 2006
but decreased afterwards to a somewhat plateau. In addition,
the rate of in-hospital mortality among patients admitted with
either a primary or a secondary diagnosis of HF declined from
DOI: 10.1161/JAHA.117.006955

2001 through 2014. Last, we found that, after publication of
the 2005 guidelines, there was a further decrease in the trend
of HF admissions as a primary or a secondary diagnosis as
well as in-hospital mortality when HF was a secondary
diagnosis.
At the beginning of the study period, the observed rate of
in-hospital mortality among hospitalizations with a primary
diagnosis of HF was more in patients aged ≥65 years, males,
and whites. However, towards the end of the study period,
there was slight closing of the gap between patients
≥65 years and those <65 years, whereas the sex gap was
no longer apparent. In contrast, the racial gap seemed to
persist, although the trends in Hispanic and Asian populations
had plateaued, whereas there was still some decreasing trend
among white and black race towards the end of the study
period. Similar to prior studies,17–19 we found that the
observed rate of in-hospital mortality for primary HF admissions was higher among whites compared with other races. A
possible explanation for this may include a higher rate of
readmission among other races (thereby increasing their
number of hospitalizations) compared with whites or a higher
mean age at hospitalization for whites (76 years versus
63 years [for blacks], 69 years [for Hispanics], and 72 years
[for Asians] in our analysis of NIS data). However, this higher
risk of in-hospital mortality persisted in whites after adjusting
for age, repeated hospitalization, and other possible confounding factors in prior studies.17,18 Hence, further studies
are needed to clearly identify the determinants of this racial
disparity.
Our ﬁndings build on and considerably expand on results of
prior studies on the trends in HF admissions from 1998
through 2009.8–10 Notably, we showed that the rate of
Journal of the American Heart Association
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Figure 3. A, Trends in in-hospital mortality in patients with a primary diagnosis of
heart failure, stratiﬁed by age. There was no signiﬁcant change in trend in the 2005
to 2009 interval (red) compared with before 2005 (blue). However, the trend
became less negative after the 2009 guidelines. B, Trends in in-hospital mortality in
patients with a primary diagnosis of heart failure, stratiﬁed by sex. There was no
signiﬁcant change in trend in the 2005 to 2009 interval compared with before
2005. However, the trend became less negative after the 2009 guidelines. C,
Trends in in-hospital mortality in patients with a primary diagnosis of heart failure,
stratiﬁed by race. There was no signiﬁcant change in trend in the 2005 to 2009
interval compared with before 2005, and the trend appeared to have plateaued
after the 2009 guidelines. CI indicates conﬁdence interval.
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Figure 4. A, Trends in admissions with heart failure (HF) as a secondary diagnosis (ie, patients with a prior
diagnosis of HF who were admitted for non-HF reasons) within intervals demarcated by the 2005 and 2009
American College of Cardiology (ACC)/American Heart Association (AHA) guidelines. There was a
signiﬁcant change in trend in the 2005 to 2009 interval (red) compared with before 2005 (blue); and after
2009 (orange) compared with the prior interval. B, Trends in in-hospital mortality in patients with HF as a
secondary diagnosis (ie, patients with a prior diagnosis of HF who were admitted for non-HF reasons),
stratiﬁed within intervals demarcated by the 2005 and 2009 ACC/AHA guidelines. There was a signiﬁcant
change in trend in the 2005 to 2009 interval (red) compared with before 2005 (blue). However, the trend
appeared to have plateaued after the 2009 guideline (orange). CI indicates conﬁdence interval.

primary HF admission continued to decline beyond the last
year (ie, 2009) in these prior studies, whereas admissions
with HF as a secondary diagnosis seem to have plateaued.
Previously, Win et al showed a declining trend in in-hospital
HF mortality from 2001 through 2010.19 However, the study
was done only among patients with diabetes mellitus. Hence,
DOI: 10.1161/JAHA.117.006955

our study is the ﬁrst to evaluate trends in HF admission
beyond 2009 in addition to providing assessment of inhospital mortality in all patients with HF from 2001 through
2014. In addition, we evaluated for the potential association
of national guidelines with rates of admission and in-hospital
mortality among patients with HF. Our analysis showed that
Journal of the American Heart Association
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Table 5. Trends in Patient- and Hospital-Level Characteristics Among Hospitalizations With HF as a Secondary Admission
Diagnosis*
Characteristics

2001–2005

2006–2009

2010–2014

Hospitalization (per 100 000 people)

1431

1427

1388

Age, mean (SD), y

74.3 (13.2)

73.6 (13.7)

72.8 (13.7)

18–<45 y, %

2.8

3.2

3.3

45–<55 y, %

6.2

7.1

7.6

55–<65 y, %

12.3

13.8

15.4

65–<75 y, %

22.0

21.7

22.7

75–<85 y, %

33.7

31.1

28.1

≥85 y, %

23.0

23.2

23.0

Female sex, %

55.9

54.3

52.4

White

77.0

74.6

72.7

Black

12.7

14

16.1

Hispanic

6.6

6.7

6.7

Asian

1.6

1.7

1.7

2.1

3.0

2.9

2.0 (2.0)

2.0 (3.0)

3.0 (2.0)

0

5.0

4.4

3.6

1

26.9

21.7

18.0

≥2

68.1

73.9

78.3

First quartile

30.9

31.4

32.2

Second quartile

26.8

27.2

26.5

Third quartile

23.2

22.6

23.1

Fourth quartile

19.1

18.9

18.2

Medicare

79.7

77.9

77.8

Medicaid

5.6

6.3

7.3

Private

11.8

12.2

11.1

Self-pay

1.5

1.9

2.0

Small

13.1

14.7

15.1

Medium

25.4

24.4

25.5

Large

61.6

60.9

59.4

Northeast

19.8

18.2

19.1

Midwest

24.7

25.2

25.4

South

39.9

40.1

39.1

West

15.6

16.6

16.3

P Value

<0.001

<0.001

<0.001

Race, %
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Others
Charlson/Deyo score, median (IQR)

†

<0.001

<0.001

Charlson/Deyo score, %
<0.001

Median household income by
zip code, %
<0.001

Expected primary payer, %‡
<0.001

Hospital bed size, %
<0.001

Hospital region, %
<0.001

Continued
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Table 5. Continued
Characteristics

2001–2005

2006–2009

2010–2014

17.2

15.3

13.2

Urban nonteaching

45.5

43.7

37.7

Urban teaching

37.3

41.1

49.1

6.0 (6.0)

5.0 (5.0)

5.0 (5.0)

0–2 d, %

19.7

21.6

22.3

3–4 d, %

23.7

25.1

26.6

≥5 d, %

56.6

53.3

51.1

P Value

Hospital location/teaching status, %
Rural

Length of stay, median (IQR), d

<0.001
<0.001
<0.001

HF indicates heart failure; and IQR, interquartile range.
*Secondary diagnosis of HF refers to patients with chronic HF who were admitted for reasons other than HF.
†
Refers to the Deyo modiﬁcation of the Charlson comorbidity score/index.
‡
Medicare and Medicaid beneﬁciaries include both fee-for-service and managed care, whereas private insurance includes Blue Cross, commercial carriers, and private health maintenance
organizations and preferred provider organizations.
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the greatest improvement in HF admission and in-hospital
mortality rates occurred after 2005, which coincides with the
publication of the 2005 ACC/AHA HF guidelines, but little
improvement was observed after release of the 2009
guidelines. A possible explanation for the improvement after
2005 includes availability of more robust evidence from
clinical trials that were incorporated into the 2005 guidelines
(eg, the recommendation for use of an implantable cardioverter deﬁbrillator for the primary prevention of sudden
cardiac death and cardiac resynchronization therapy for
patients with ventricular dyssynchrony were ﬁrst incorporated
into the 2005 update of the 2001 guidelines). In addition,
compared with the 2001 guidelines, the 2005 update
provided a more speciﬁc and evidence-based indication for
use of available HF therapies (eg, the use of hydralazine and
isosorbide dinitrate in blacks with HF with a reduced ejection
fraction). On the other hand, there was no major change in
therapy in the 2009 guidelines.
Potential limitations of this study should also be considered. First, because of the observational nature of the study, it
is impossible to claim that the change in trends after
publication of the guidelines was as a result of the guidelinedirected care. In other words, our ﬁndings represent an
association, but not causation, because other variables not
evaluated in this study could have also contributed to this
change in trend. Second, HF hospitalizations were identiﬁed
via ICD-9-CM codes for which it is possible that the coding
preference has changed during the study period. We,
however, mitigate against this by identifying our patient
population using an extensive number of ICD-9-CM codes that
were recommended by the ACC/AHA task force on performance measure. Third, the NIS is a sampling of hospitalizations rather than unique patients, which may contribute >1
hospitalization from readmissions. This is a general limitation
DOI: 10.1161/JAHA.117.006955

of most hospital discharge databases, such as NIS, which,
unfortunately, could not be adjusted for because patients are
deidentiﬁed in the database. Our analysis, therefore, represents a composite of both ﬁrst admission (during the study
period) and readmissions, which is of great value in contemporary analysis of HF data. Hence, our admission rates should
be interpreted as number of total hospitalizations per US
population, whereas mortality rates represent mortalityassociated hospitalizations per total hospitalizations in that
year.
In summary, despite an increase in comorbidity burden,
primary HF hospitalization and HF-associated (ie, HF as the
primary or the secondary diagnosis) in-hospital mortality
declined in the United States between 2001 and 2014. There
seems to be a further decline in HF-associated admissions
and in-hospital mortality among patients with a secondary
diagnosis of HF after the publication of the 2005 ACC/AHA
HF management guidelines compared with the preceding
trend. However, little further improvement was observed
beyond 2009 during the study period.
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SUPPLEMENTAL MATERIAL

Table S1. Deyo’s modification of Charlson comorbidity index
Comorbidities
Myocardial infarction
Congestive heart failure
Peripheral vascular disease

ICD-9-CM codes

score

410.x, 412.x

1

428.x

1

443.9, 441.x, 785.4, V43.4,

1

procedure 38.48
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Downloaded from http://jaha.ahajournals.org/ by guest on December 2, 2017

Rheumatic disease

430.x-438.x

1

290.x

1

490.x-505.x, 506.4

1

710.0, 710.1, 710.4, 714.0-

1

714.2, 714.81. 725.x
Peptic ulcer disease

531.x-534.x

1

Mild liver disease

571.2, 571.4-571.6

1

Diabetes without chronic

250.0-250.3, 250.7

1

250.4-250.6

2

344.1, 342.x

2

582.x, 583-583.7, 585.x,

2

complication
Diabetes with chronic
complication
Hemiplegia or paraplegia
Renal disease

586.x, 588.x
Any malignancy, including

140.x-172.x, 174.x-195.8,

2

lymphoma and leukemia

200.x-208.x

Moderate or severe liver

456.0-456.21, 572.2-572.8

3

Metastatic solid tumor

196.x-199.1

6

AIDS/HIV

042.x-044.x

6

disease

Abbreviations: ICD-9-CM, International Classification of Diseases-Ninth Revision, Clinical
Modification

Table S2. Primary heart failure admission by survival status
Total

Survived till

In-hospital

hospital

mortality

P value

discharge
Unweighted No. (%)
Weighted No. (%)

3,058,789 (100)

2,951,127 (96.5)

107,662 (3.5)

14,616,729

14,105,104 (96.5)

511,626 (3.5)

(100)
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Age [years], mean (SD)

72.6 (14.2)

72.4 (14.3)

78.6 (12.2)

18 to <45 years, %

4.2

4.2

1.6

45 to <55 years, %

8.3

8.5

3.3

55 to <65 years, %

14.4

14.6

7.8

65 to <75 years, %

21.3

21.5

16.9

75 to <85 years, %

29.5

29.4

33.9

≥85 years, %

22.3

21.8

36.5

51.5

51.5

51.4

White

68.3

67.9

78.4

Black

19.4

19.7

11.0

Hispanic

7.9

8.0

6.3

Asian

1.7

1.8

1.7

Others

2.6

2.6

2.5

2.0 (2.0)

2.0 (2.0)

2.0 (2.0)

0

19.8

19.8

18.9

1

26.2

26.4

21.7

≥2

54.0

53.8

59.4

1st quartile

33.4

33.5

30.5

2nd quartile

26.7

26.7

26.6

Female, %

<0.001

<0.001

0.61

Race, %

Charlson/Deyo score‡,

<0.001

median (IQR)
Charlson/Deyo score, %
<0.001

Median household income
by Zip code, %
<0.001

3rd quartile

22.3

22.3

23.0

4th quartile

17.6

17.6

20.0

Medicare

75.2

75.0

81.5

Medicaid

7.6

7.7

4.0

Private

12.3

12.4

10.5

Self-pay

3.0

3.0

1.5

Small

14.8

14.8

14.8

Medium

25.7

25.7

25.3

Large

59.5

59.5

59.9

Northeast

19.9

19.8

22.4

Midwest

23.1

23.2

21.7

South

41.8

41.8

40.6

West

15.2

15.2

15.3

Rural

16.2

16.1

17.5

Urban non-teaching

43.5

43.5

44.3

Urban teaching

40.3

40.4

38.2

4.0 (4.0)

4.0 (4.0)

5.0 (8.0)

0-2 days, %

25.8

25.6

29.7

3-4 days, %

31.5

32.0

17.7

≥5 days, %

42.8

42.4

52.6

Expected primary payer, %

<0.001

Hospital bed size, %
<0.001
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Hospital region, %
<0.001

Hospital location/teaching
status, %

Length of stay [days],

<0.001
<0.001

median (IQR)
<0.001

Abbreviations: SD, standard deviation; IQR, interquartile range
‡Refers to Deyo’s modification of Charlson Comorbidity score/index
¶

Medicare and Medicaid beneficiaries include both fee-for-service and managed care while
private insurance includes Blue Cross, commercial carriers, and private HMOs and PPOs

Table S3. Secondary† heart failure admission by survival status
Total

Survived till

In-hospital

hospital discharge

mortality
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Unweighted No. (%)

8,949,037 (100)

8,354,695 (93.4)

594,342 (6.6)

Weighted No. (%)

42,733,720 (100)

39,925,855 (93.4)

2,807,864 (6.6)

Age [years], mean (SD)

73.5 (13.6)

73.2 (13.6)

77.4 (12.2)

18 to <45 years, %

3.1

3.2

1.6

45 to <55 years, %

7.0

7.2

3.8

55 to <65 years, %

13.9

14.2

9.3

65 to <75 years, %

22.2

22.4

19.0

75 to <85 years, %

30.8

30.6

34.1

≥85 years, %

23.0

22.4

32.3

54.1

54.3

52.1

White

74.5

74.3

77.1

Black

14.5

14.7

11.4

Hispanic

6.6

6.6

6.6

Asian

1.7

1.6

2.2

Others

2.7

2.7

2.8

2.0 (3.0)

2.0 (3.0)

3.0 (2.0)

0

4.3

4.5

1.8

1

22.1

22.3

18.7

≥2

73.6

73.2

79.5

1st quartile

31.5

31.7

29.6

2nd quartile

26.8

26.9

26.3

3rd quartile

23.0

23.0

23.3

4th quartile

18.7

18.6

20.8

Female, %

P value

<0.001

<0.001

<0.001

Race, %

Charlson/Deyo score‡,

<0.001

median (IQR)
Charlson/Deyo score, %
<0.001

Median household income by
Zip code, %
<0.001

Expected primary payer¶, %
Medicare

78.5

78.2

81.8

Medicaid

6.4

6.6

4.4

Private

11.7

11.8

10.3

Self-pay

1.8

1.8

1.5

Small

14.3

14.3

13.8

Medium

25.2

25.2

25.2

Large

60.6

60.6

61.0

Northeast

19.1

18.9

21.6

Midwest

25.1

25.4

21.5

South

39.6

39.7

39.1

West

16.1

16.0

17.8

Rural

15.1

15.2

14.2

Urban non-teaching

42.0

41.9

44.0

Urban teaching

42.8

42.9

41.8

5.0 (5.0)

5.0 (5.0)

6.0 (10)

0-2 days, %

21.3

20.8

27.5

3-4 days, %

25.2

25.9

15.6

≥5 days, %

53.6

53.3

57.0

<0.001

Hospital bed size, %
<0.001

Hospital region, %
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<0.001

Hospital location/teaching
status, %

Length of stay [days], median

<0.001
<0.001

(IQR)
<0.001

Abbreviations: SD, standard deviation; IQR, interquartile range
†Secondary diagnosis of heart failure refers to patients with chronic heart failure who were
admitted for reasons other than heart failure
‡Refers to Deyo’s modification of Charlson Comorbidity score/index
¶

Medicare and Medicaid beneficiaries include both fee-for-service and managed care while
private insurance includes Blue Cross, commercial carriers, and private HMOs and PPOs
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